{"filing":{"accession_number":"0001193125-26-286926","cik":"0002112446","ticker":"JATT","company_name":"JATT II Acquisition Corp.","form":"8-K","filing_date":"2026-06-29","report_date":null,"primary_document":"d136998d8k.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/2112446/000119312526286926/d136998d8k.htm"},"events":[{"id":14501,"run_id":12914,"accession_number":"0001193125-26-286926","anchor_item_number":"1.01","event_type":"ma_activity","event_domain":"operational","is_material":true,"confidence":0.99,"summary":"JATT II Acquisition Corp entered into a definitive Business Combination Agreement with Talawar Tx Inc. on June 29, 2026, whereby Merger Sub will merge with and into JATT, with JATT surviving as a wholly-owned subsidiary of Talawar. The transaction involves $285 million in combined proceeds ($60 million from trust account plus $225 million PIPE financing) and is expected to close in H2 2026, with the combined entity listing on Nasdaq under ticker \"TLWR.\"","company_name":"JATT II Acquisition Corp.","ticker":"JATT","filing_date":"2026-06-29","form":"8-K","submitted_at":null,"items":[{"id":11962,"accession_number":"0001193125-26-286926","item_number":"1.01","item_title":null,"event_type":"ma_activity","event_domain":"operational","is_material":true,"confidence":0.99,"reasoning":"JATT II Acquisition Corp entered into a definitive Business Combination Agreement with Talawar Tx Inc. on June 29, 2026, whereby Merger Sub will merge with and into JATT, with JATT surviving as a wholly-owned subsidiary of Talawar. This is a material change of control transaction involving a SPAC merger with an anticipated $285 million in combined proceeds ($60 million from trust account plus $225 million PIPE financing), expected to close in H2 2026 and list on Nasdaq under ticker \"TLWR.\" The transaction is clearly a material acquisition/merger activity under Item 1.01.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-06-29T12:38:47.517265+00:00","company_name":"","ticker":null,"filing_date":""},{"id":11963,"accession_number":"0001193125-26-286926","item_number":"3.02","item_title":null,"event_type":"dilutive_issuance","event_domain":"financial","is_material":true,"confidence":0.95,"reasoning":"Item 3.02 discloses an unregistered sale of Company Common Stock to PIPE Investors pursuant to PIPE Subscription Agreements in reliance on Section 4(a)(2) exemption. The press release confirms a $225 million oversubscribed PIPE at $10.00 per share with participation from major healthcare investors (Access Biotechnology, Bain Capital Life Sciences, Deep Track Capital, RA Capital, etc.). This is a classic private investment in public equity (PIPE) concurrent with a SPAC business combination, representing a material dilutive issuance of unregistered equity securities.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-06-29T12:38:47.517265+00:00","company_name":"","ticker":null,"filing_date":""},{"id":11964,"accession_number":"0001193125-26-286926","item_number":"7.01","item_title":null,"event_type":"ma_activity","event_domain":"operational","is_material":true,"confidence":0.98,"reasoning":"The filing discloses entry into a definitive business combination agreement between Talawar Therapeutics and JATT II Acquisition Corp, with expected closing in H2 2026. The transaction involves a $225 million oversubscribed PIPE and $60 million from JATT II's trust account, creating a publicly listed biotechnology company. This is a material acquisition/change of control event requiring shareholder approval, disclosed via Item 7.01 with supporting press release and investor presentation.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-06-29T12:38:47.517265+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":11962,"accession_number":"0001193125-26-286926","item_number":"1.01","item_title":null,"event_type":"ma_activity","event_domain":"operational","is_material":true,"confidence":0.99,"reasoning":"JATT II Acquisition Corp entered into a definitive Business Combination Agreement with Talawar Tx Inc. on June 29, 2026, whereby Merger Sub will merge with and into JATT, with JATT surviving as a wholly-owned subsidiary of Talawar. This is a material change of control transaction involving a SPAC merger with an anticipated $285 million in combined proceeds ($60 million from trust account plus $225 million PIPE financing), expected to close in H2 2026 and list on Nasdaq under ticker \"TLWR.\" The transaction is clearly a material acquisition/merger activity under Item 1.01.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-06-29T12:38:47.517265+00:00","company_name":"JATT II Acquisition Corp.","ticker":"JATT","filing_date":"2026-06-29"},{"id":11963,"accession_number":"0001193125-26-286926","item_number":"3.02","item_title":null,"event_type":"dilutive_issuance","event_domain":"financial","is_material":true,"confidence":0.95,"reasoning":"Item 3.02 discloses an unregistered sale of Company Common Stock to PIPE Investors pursuant to PIPE Subscription Agreements in reliance on Section 4(a)(2) exemption. The press release confirms a $225 million oversubscribed PIPE at $10.00 per share with participation from major healthcare investors (Access Biotechnology, Bain Capital Life Sciences, Deep Track Capital, RA Capital, etc.). This is a classic private investment in public equity (PIPE) concurrent with a SPAC business combination, representing a material dilutive issuance of unregistered equity securities.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-06-29T12:38:47.517265+00:00","company_name":"JATT II Acquisition Corp.","ticker":"JATT","filing_date":"2026-06-29"},{"id":11964,"accession_number":"0001193125-26-286926","item_number":"7.01","item_title":null,"event_type":"ma_activity","event_domain":"operational","is_material":true,"confidence":0.98,"reasoning":"The filing discloses entry into a definitive business combination agreement between Talawar Therapeutics and JATT II Acquisition Corp, with expected closing in H2 2026. The transaction involves a $225 million oversubscribed PIPE and $60 million from JATT II's trust account, creating a publicly listed biotechnology company. This is a material acquisition/change of control event requiring shareholder approval, disclosed via Item 7.01 with supporting press release and investor presentation.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-06-29T12:38:47.517265+00:00","company_name":"JATT II Acquisition Corp.","ticker":"JATT","filing_date":"2026-06-29"}]}